Navigation Links
ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe

DENVER and GOLDEN, Colo., March 3 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today the finalization of a reverse distribution agreement with Osenses Pty. Ltd., an Australian-based manufacturer of life science reagents. Further expanding its already extensive portfolio of 100% quality guaranteed research antibodies, ABR is now an authorized distributor of Osenses products in the U.S., Europe and Canada.

Osenses offers primary antibodies for experimental use in the areas of chemosensory receptors (olfactory, vomeronasal and trace amine-associated), and visual, auditory and transient receptors. According to Ken Wilczek, President of ABR-Affinity BioReagents, "Partnering with Osenses enhances our ability to offer experimental research tools to scientists who are active in the increasingly important realm of sensory neuronal research." Encompassing antibodies for olfactory receptors, market proteins and stem cells, the Osenses product line will round out ABR's existing antibody portfolio, which now comprises more than 36,000 quality-guaranteed antibodies and research reagents.

"This type of reverse distribution arrangement allows us to utilize our already strong sales channels to really help get these unique products into the hands of research scientists who are performing cutting edge research on a daily basis," noted Ken Wilczek, President of ABR. Beginning in 2005, ABR-Affinity BioReagents implemented a strategy to investigate and partner with select worldwide antibody suppliers who produce quality products for distribution through ABR into the U.S. Other reverse distribution partners currently include: Abnova, Ab Frontier, Antibody Shop, Good Biotech and Genesis.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand.

With more than 36,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry-research antibodies that are 100% quality guaranteed or your money back-with no questions asked.

Utilizing a distribution network encompassing over 60 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.

SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
2. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
3. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Touch Bionics signs U.S. distribution agreement with SPS
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
10. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):